Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipel

BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the undefi

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: OR

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and mainta

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains

Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the ana

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected i

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains

Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing

UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the pric

This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing

Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weig

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects,

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside i

 On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment

This clinical-stage biotech focused on antibody therapies for immunological disorders reported a not

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORK

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains

Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analy

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, wi

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other imm

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional

https://www.sec.gov/Archives/edgar/data/907654/000121390026049372/ea0288174-424b5_oruka.htm

Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind,

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) wit

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a cl

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate

UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the pric

Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and ra

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moder

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on develo

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a cl

Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for OR

BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the

Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following posi

Oruka Therapeutics shares rise as ORKA-001 shows strong psoriasis clearance rates and durable dosing

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16Favorable safety profile consistent with the IL-2

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up

Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and rais

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and mainta

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) wit